Investigating the Potential of Transmucosal Delivery of Febuxostat from Oral Lyophilized Tablets Loaded with a Self-Nanoemulsifying Delivery System
Gout is the most familiar inflammatory arthritis condition caused by the elevation of uric acid in the bloodstream. Febuxostat (FBX) is the latest drug approved by the United States Food and Drug Administration (US FDA) for the treatment of gout and hyperuricemia. FBX is characterized by low solubil...
Main Authors: | Yasir A. Al-Amodi, Khaled M Hosny, Waleed S. Alharbi, Martin K. Safo, Khalid M El-Say |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-06-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/12/6/534 |
Similar Items
-
Self-Nanoemulsifying System Loaded with Sildenafil Citrate and Incorporated within Oral Lyophilized Flash Tablets: Preparation, Optimization, and In Vivo Evaluation
by: Khaled M. Hosny, et al.
Published: (2020-11-01) -
Self-nanoemulsifying ramipril tablets: a novel delivery system for the enhancement of drug dissolution and stability
by: Alhasani KF, et al.
Published: (2019-07-01) -
Febuxostat in the therapy of gout: from theory to practice
by: E. V. Ilyinykh, et al.
Published: (2018-01-01) -
Introducing Self-Nanoemulsifying Drug Delivery System to Increase the Bioavailability of Oral Medications
by: Razieh Nazari-Vanani, et al.
Published: (2018-11-01) -
Design and optimization of self-nanoemulsifying drug delivery systems for improved bioavailability of cyclovirobuxine D
by: Ke ZC, et al.
Published: (2016-06-01)